The Enterprise Value as of September 2024 (TTM) for UroGen Pharma Ltd. (URGN) is 429.93M

According to UroGen Pharma Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 429.93M. This represents a change of -9.74% compared to the average of 476.31M of the last 4 quarters.

UroGen Pharma Ltd. (URGN) Historical Enterprise Value (quarterly & annually)

How has URGN Enterprise Value performed in the past?

The mean historical Enterprise Value of UroGen Pharma Ltd. over the last ten years is 301.87M. The current 429.93M Enterprise Value has changed 14.14% with respect to the historical average. Over the past ten years (40 quarters), URGN's Enterprise Value was at its highest in in the June 2019 quarter at 671.76M. The Enterprise Value was at its lowest in in the December 2015 quarter at 14.19M.

UroGen Pharma Ltd. (URGN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of UroGen Pharma Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

UroGen Pharma Ltd. (URGN) Average Enterprise Value

How has URGN Enterprise Value performed in the past?

The current Enterprise Value of UroGen Pharma Ltd. (URGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

UroGen Pharma Ltd. (URGN) Enterprise Value vs. Peers

How is URGN’s Enterprise Value compared to its peers?

UroGen Pharma Ltd.’s Enterprise Value is greater than Eliem Therapeutics, Inc. (312.10M), greater than Inhibrx, Inc. (21.26M), greater than Merrimack Pharmaceuticals, Inc. (-10189682.00), less than Celcuity Inc. (621.87M), less than Enliven Therapeutics, Inc. (931.13M), greater than Ikena Oncology, Inc. (44.93M), greater than Xilio Therapeutics, Inc. (-30458906.00), greater than Protara Therapeutics, Inc. (-44987784.00), less than Scholar Rock Holding Corporation (636.54M), greater than Vaccitech plc (45.13M), greater than Generation Bio Co. (238.32M), greater than Kronos Bio, Inc. (12.40M), less than Erasca, Inc. (697.60M), less than C4 Therapeutics, Inc. (437.68M), less than Edgewise Therapeutics, Inc. (1.75B), greater than Ovid Therapeutics Inc. (61.90M), greater than Connect Biopharma Holdings Limited (-40618512.00), greater than PepGen Inc. (255.11M), less than Tyra Biosciences, Inc. (1.13B), greater than Compass Therapeutics, Inc. (202.01M), greater than Vigil Neuroscience, Inc. (113.67M), greater than PureTech Health plc (248.59M),

Build a custom stock screener for UroGen Pharma Ltd. (URGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like UroGen Pharma Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

UroGen Pharma Ltd. (URGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like UroGen Pharma Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.